Medline Inc. · MDLN · FY2026 Q3 · Calendar Q4 2026
Medline Raises 2026 Organic Sales Outlook on 10% Q3 Growth
Medline’s 10% Q3 sales growth, customer signings and higher full-year organic-sales outlook point to continued business momentum; inflation, capacity spending and quality work remain counterweights to profitability.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about MDLN FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with Q2, management reported 10% Q3 sales growth and raised the 2026 organic-sales outlook to 10–10.5%, following its earlier 9–10% outlook. It also reaffirmed adjusted EBITDA guidance.
Guidance delta
Raised 2026 organic-sales guidance to 10–10.5%; adjusted EBITDA guidance was reaffirmed.
Key takeaways
- Q3 sales grew 10% year over year to $7.9 billion; Medline Brand rose 7% and Supply Chain Solutions rose 14%.
- Adjusted EBITDA was $1 billion, up 12%; year-to-date free cash flow was $1.8 billion.
- Management cited new customer signings, prime-vendor contracts and brand-conversion opportunities as growth drivers.
Management priorities
- Build four distribution centers and expand automation, including at Tracy.
- Continue the global quality action plan and third-party assessments.
- Pursue the restructuring program targeting $80–$90 million in annual savings and implement the planned Q1 2027 price increase.
Follow MDLN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationMedline Inc. is a global manufacturer of medical and surgical products, catering to a broad spectrum of healthcare providers. Their clientele includes hospitals, surgical centers, physician practices, post-acute care facilities, and nursing homes, both domestically and worldwide. The company's operations are divided into two primary divisions: the Medline Brand and Supply Chain Solutions. The Medline Brand division focuses on the production and sourcing of its proprietary medical products, categorized into three key areas: Within Frontline Care, Medline provides a wide array of patient-facing medical and surgical items. This encompasses essentials like wound care treatments, examination gloves, skin and incontinence products, sanitation supplies, various textiles, hand sanitizers, durable medical equipment (DME), patient-specific plastic goods, and decolonization and infection control solutions. The Surgical Solutions category delivers comprehensive product lines for operating rooms and perioperative settings.…
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RPRX Royalty Pharma plc | FY2026 Q3 · Calendar Q4 2026 | — | +1.4% | Royalty Pharma Raises Guidance as Receipts and Co-Funding Expand |
| ZBH Zimmer Biomet Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +14.6% | Zimmer Biomet raises 2026 outlook as hip and technology growth offset knee weakness |
| NVO Novo Nordisk A/S | FY2026 Q3 · Calendar Q4 2026 | — | +6.4% | Novo Nordisk Q3: obesity demand supports growth, pricing and LOE remain risks |
| CRL Charles River Laboratories International, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -6.0% | Charles River raises FY2026 outlook after strong Q3; demand and margins improve |
| UTHR United Therapeutics Corporation | FY2026 Q3 · Calendar Q4 2026 | — | +0.6% | United Therapeutics’ record quarter highlights Tyvaso growth and pipeline execution |
| AMGN Amgen Inc. | FY2026 Q3 · Calendar Q4 2026 | +11.4% | +1.6% | Amgen Q3: Growth Drivers, Pipeline Progress and Higher 2026 Guidance |
Latest beats and misses
Who reports nextBeat on EPS
- WTRGFY2026 Q3 · November 3, 2026+13.7% EPS+2.5% move
- LTMFY2026 Q3 · November 3, 2026+25.2% EPS+9.5% move
- AIZFY2026 Q3 · November 3, 2026+29.5% EPS+4.2% move
- AIZNFY2026 Q3 · November 3, 2026+36.0% EPS+0.5% move
- SMCIFY2027 Q1 · November 3, 2026+47.2% EPS-4.2% move
- XYZFY2026 Q3 · November 3, 2026+9.7% EPS+14.9% move
Missed on EPS
- BSACFY2026 Q3 · October 30, 2026-20.0% EPS-3.0% move
- TXFY2026 Q3 · November 3, 2026-24.9% EPS-0.0% move
- CHTFY2026 Q3 · November 4, 2026-55.7% EPS+0.9% move
- TOSTFY2026 Q3 · November 3, 2026-20.1% EPS+5.9% move
- CPNGFY2026 Q3 · November 3, 2026-90.3% EPS+13.3% move
- TLNFY2026 Q3 · November 3, 2026-65.4% EPS+7.3% move
Get the MDLN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-04T18:13:59.156222+00:00
- FN2 earnings calendar · 2026-11-04T01:23:13.345574+00:00
- Polygon adjusted daily market bars · 2026-11-04T19:20:49.663574+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-04T19:20:49.660913+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-04. For educational purposes only; not investment advice.